Trial Profile
A study to investigate the adherence and effectiveness of nebulized colistimethate sodium (Promixin) in patients with non-cystic fibrosis bronchiectasis colonized by Pseudomonas aeruginosa (PsA).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Jan 2016
Price :
$35
*
At a glance
- Drugs Colistimethate sodium (Primary)
- Indications Cystic fibrosis-associated respiratory tract infections; Pseudomonal infections
- Focus Therapeutic Use
- 13 Jan 2016 New trial record